Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXR NASDAQ:PPBT NASDAQ:QTTB NASDAQ:SONN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$1.33-5.0%$1.49$0.65▼$15.25$23.82M1.19341,734 shs2.36 million shsPPBTPurple Biotech$1.99-12.3%$2.35$1.94▼$13.95$5.87M0.4919,239 shs89,438 shsQTTBQ32 Bio$1.71-3.4%$1.91$1.35▼$53.79$21.59MN/A142,043 shs43,892 shsSONNSonnet BioTherapeutics$3.25-3.8%$3.86$1.08▼$19.30$23.08M1.04684,217 shs336,534 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals-5.00%-1.48%-4.32%+92.36%-90.79%PPBTPurple Biotech-12.33%-13.48%-4.33%-26.30%+198,999,900.00%QTTBQ32 Bio-3.39%-10.47%-17.39%-2.29%-95.57%SONNSonnet BioTherapeutics-3.85%-6.34%+0.93%+176.60%-44.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTXRCitius Pharmaceuticals2.7816 of 5 stars3.34.00.00.02.20.81.3PPBTPurple Biotech1.8101 of 5 stars3.52.00.00.02.20.00.6QTTBQ32 Bio2.6706 of 5 stars3.14.00.00.01.72.50.6SONNSonnet BioTherapeutics3.4428 of 5 stars3.54.00.00.03.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.50Moderate Buy$53.003,884.96% UpsidePPBTPurple Biotech 3.00Buy$33.001,558.29% UpsideQTTBQ32 Bio 2.25Hold$12.17611.50% UpsideSONNSonnet BioTherapeutics 3.00Buy$20.00515.38% UpsideCurrent Analyst Ratings BreakdownLatest PPBT, SONN, QTTB, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.006/30/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.006/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius PharmaceuticalsN/AN/AN/AN/A$3.97 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$12.40 per shareN/AQTTBQ32 Bio$1.16M17.98N/AN/A($1.00) per share-1.71SONNSonnet BioTherapeutics$20K1,109.88N/AN/A($0.45) per share-7.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$39.14MN/A0.001.06N/AN/A-60.03%-33.83%N/APPBTPurple Biotech-$7.24M-$0.42N/AN/AN/AN/A-14.00%-12.52%N/AQTTBQ32 Bio-$47.73M-$4.30N/AN/AN/AN/A-2,709.70%-61.16%11/6/2025 (Estimated)SONNSonnet BioTherapeutics-$7.44MN/A0.00∞N/AN/A-4,646.10%-342.21%N/ALatest PPBT, SONN, QTTB, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025SONNSonnet BioTherapeutics-$0.49-$0.95-$0.46-$0.95N/AN/A8/12/2025Q3 2025CTXRCitius Pharmaceuticals-$0.76-$0.80-$0.04-$0.80$1.92 million$1.92 million8/6/2025Q2 2025PPBTPurple Biotech-$0.21-$0.40-$0.19-$0.40N/AN/A8/6/2025Q2 2025QTTBQ32 Bio-$1.14-$0.78+$0.36-$0.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ASONNSonnet BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.470.14PPBTPurple BiotechN/A2.882.88QTTBQ32 Bio1.685.065.06SONNSonnet BioTherapeuticsN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%PPBTPurple Biotech9.64%QTTBQ32 Bio31.32%SONNSonnet BioTherapeutics9.45%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals10.70%PPBTPurple Biotech2.98%QTTBQ32 Bio40.00%SONNSonnet BioTherapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2017.01 million15.19 millionOptionablePPBTPurple Biotech202.59 million2.51 millionOptionableQTTBQ32 Bio3912.20 million7.32 millionN/ASONNSonnet BioTherapeutics106.83 million6.69 millionNot OptionablePPBT, SONN, QTTB, and CTXR HeadlinesRecent News About These CompaniesBiotechs Turn to Digital Coins, Crypto to Boost Stock PricesAugust 25, 2025 | msn.comSonnet BioTherapeutics (NASDAQ:SONN) Upgraded at Wall Street ZenAugust 19, 2025 | americanbankingnews.comSonnet Biotherapeutics Faces Earnings Volatility with New HYPE Treasury Strategy and Accounting StandardsAugust 15, 2025 | msn.comSonnet Releases Virtual Investor "What This Means" SegmentAugust 11, 2025 | globenewswire.comThis Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?August 6, 2025 | msn.comSonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian CancerAugust 4, 2025 | globenewswire.comBeyond BTC and ETH: The Companies Turning to Alternative Crypto Treasury AssetsAugust 2, 2025 | msn.comSonnet BioTherapeutics Appoints Interim CEO Raghu RaoAugust 1, 2025 | tipranks.comSolana-based treasury model goes global as DeFi Development launches franchiseJuly 17, 2025 | msn.comWLFI tokens to become tradable after World Liberty holders’ voteJuly 17, 2025 | msn.comHyperliquid Strategies Inc. plan for $583M treasury boosts HYPE priceJuly 16, 2025 | cointelegraph.comSonnet BioTherapeutics Merges in $888M Deal to Launch Hyperliquid Strategies and HYPE TreasuryJuly 15, 2025 | thecurrencyanalytics.comTSonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays ExuberantJuly 15, 2025 | msn.comPublic Firm Sonnet BioTherapeutics to Launch HyperLiquid Treasury in New DealJuly 14, 2025 | coinspeaker.comSonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.July 14, 2025 | marketwatch.comWhy did Sonnet BioTherapeutics (SONN) Shares Gain over 200% in Premarket Trading?July 14, 2025 | tokenist.comTHyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrandJuly 14, 2025 | fxstreet.comHYPE coin price up 200%, Sonnet BioTherapeutics merges into Hyperliquid StrategiesJuly 14, 2025 | msn.comMassive deal sends biotech stock rallying 367%July 14, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)July 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePPBT, SONN, QTTB, and CTXR Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$1.33 -0.07 (-5.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.33 0.00 (-0.30%) As of 08/29/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Purple Biotech NASDAQ:PPBT$1.99 -0.28 (-12.33%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$2.00 +0.01 (+0.25%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.Q32 Bio NASDAQ:QTTB$1.71 -0.06 (-3.39%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.72 +0.02 (+0.88%) As of 08/29/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Sonnet BioTherapeutics NASDAQ:SONN$3.25 -0.13 (-3.85%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.29 +0.04 (+1.23%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
